Ryan Brudner
Research affiliate in psychiatry at the University of Toronto / affiliated with the Mood Disorder Psychopharmacology Unit and related psilocybin research teams
Data updated
Papers
Trials
Research Footprint
Ryan Brudner appears in 5 tracked papers (2024–2025), most studied alongside Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Bipolar Disorder.
Most-cited paper: Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin (89 citations).
Frequent co-authors: Zoe Doyle, Roger McIntyre and Jonathan Rosenblat.
Background & Research
Ryan M Brudner appears to be a researcher based in Toronto involved in psychiatry and psychedelic clinical research. He is listed as a coauthor on several psilocybin-assisted psychotherapy papers from the University of Toronto/UHN-associated research network, including studies on treatment-resistant depression, mystical experience, bipolar II disorder, and cognitive outcomes.
Key Impact
He is a coauthor on multiple clinical studies of psilocybin-assisted psychotherapy for treatment-resistant depression, including randomized trial analyses and related outcome papers.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Ryan Brudner is associated with.
Brain and Cognition Discovery Foundation
Non-ProfitCanada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →